The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,282.50
Bid: 1,285.00
Ask: 1,285.50
Change: 0.00 (0.00%)
Spread: 0.50 (0.039%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,282.50
PSN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

25 Apr 2018 07:00

RNS Number : 9986L
Persimmon PLC
25 April 2018
 

TRADING UPDATE

 

WEDNESDAY 25 APRIL 2018

 

Persimmon plc ("the Group") announces the following trading update covering the period from 1 January 2018 to date, ahead of its Annual General Meeting ("AGM") which is being held at 12.00 noon today.

 

The Group continues to focus on building family housing at affordable prices across the UK. Customer activity since the start of the year has been encouraging with the Group's total enquiry levels running c. 13% ahead of the prior year. This has resulted in robust trading since the start of the year with visitor levels to site, sales conversion rates and cancellation rates all running in line with our expectations.

 

The Group's forward sales position remains very strong with total forward sales revenue, including legal completions taken to date in 2018, of £2.76 billion, being c.8% higher than last year (2017: £2.56 billion). Our weekly private sales rate per site since the start of the year of c. 0.85 (2017: c. 0.83) reflects solid market conditions. We have 9,048 (2017: 8,928) new homes sold forward into the private ownership market with an average selling price of c. £236,500 (2017: c. £229,500). Pricing conditions remain firm across our regional markets. The Group has also maintained a substantial forward order book of new homes for delivery to its Housing Association partners, with 5,330 (2017: 4,616) new homes included in our forward sales position.

 

The Group has opened 65 of the c. 100 new sites planned for the first half of the year and is building new homes on all sites that have an implementable detailed planning consent. The Group is currently developing 375 active sales outlets across the UK. During the period we continued to identify good opportunities to acquire new land on a selective basis to support the future growth of the business.

To help meet demand for new housing in all of its regional markets and to support the sustainable growth of the Group, six new operating businesses have been opened over the last three years, bringing the total regional house building businesses to 30. Since the launch of the Group's new strategy in 2012 the Group has built and sold over 80,000 new homes across the UK.

 

The development of our off-site manufacturing capability will play an increasingly important role in supporting the expansion of our new home construction volumes. Our manufacturing hub at Harworth, Doncaster where the Group continues to invest in new manufacturing capacity to help improve the supply of essential construction materials is a major differentiator for Persimmon. In 2017 the Group opened a new brick manufacturing factory and has announced it is to establish a new roof tile manufacturing facility during 2018 to further strengthen the reliability of our new home delivery and to support further growth. In addition, the Board will continue to review plans for the expansion of the Group's Space4 business to extend its reach for the supply of timber frames, highly insulated wall panels and roof cassettes to Group companies across the UK.

 

Exercising capital discipline through the cycle whilst growing the business as market conditions allow are key features of the Group's strategy. Our Capital Return Plan ("the Plan") to return surplus capital to shareholders continues to be a fundamental element of this capital discipline. The Group's successful trading performance over the six years to the end of 2017, increasing annual output by over 70% and opening 1,189 new sales outlets whilst investing c. £3.2 billion in land, has enabled the Board to increase the total value of the Plan. In total, the Group has generated £2.77 billion of free cash before the return of surplus capital over the six years since the launch of the Group's strategy.

 

As announced on 27 February 2018, additional payments under the Plan of 125p per share will be paid over the next three years in late March/early April each year. The first of these additional payments of £389 million, was paid to shareholders as an interim dividend on 29 March 2018. At the same time the Board recommended that the scheduled return of 110p per share, or c. £345 million, will be paid to shareholders on 2 July 2018 as a final dividend. With the scheduled payment on 2 July 2018, the total value of the capital returned by that date of £2.22 billion will be £1.36 billion greater than that originally planned at launch in 2012.

 

The additional payments over the next three years will bring the total value of the Plan to £13.00 per share, more than double the £6.20 per share original commitment made by the Board in 2012. The total value of the Plan is now c. £4.07 billion.

 

Total shareholder returns to date from the launch of the Group's new strategy in 2012 now exceed 500%.

 

The Board remains confident of the future prospects of the Group.

 

We will provide a further report in our Trading Update on Thursday 5 July 2018.

 

 

 

For further information please contact:

 

 

Jeff Fairburn, Group Chief Executive

Simon Rigby

Mike Killoran, Group Finance Director

Kevin Smith

Persimmon plc

Jos Bieneman

Citigate Dewe Rogerson

Tel: +44 (0) 1904 642199

Tel: +44 (0) 20 7638 9571

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKMGZDVDRGRZM
Date   Source Headline
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company
8th Nov 20237:00 amRNSAppointment of Chief Financial Officer
7th Nov 20237:00 amRNSQ3 Trading Statement
3rd Nov 20231:15 pmRNSHolding(s) in Company
1st Sep 20231:15 pmRNSTotal Voting Rights
10th Aug 20237:04 amRNSHalf Year Results
27th Jul 202310:13 amRNSDirectorate Change
10th Jul 20239:27 amRNSDirector Declaration
3rd Jul 20232:46 pmRNSTotal Voting Rights
1st Jun 20234:38 pmRNSTR-1: Notification of major holdings
1st Jun 20231:07 pmRNSBlock listing Interim Review
1st Jun 202311:06 amRNSTotal Voting Rights
3rd May 20235:00 pmRNSHolding(s) in Company
3rd May 20234:12 pmRNSDirector/PDMR Shareholding
2nd May 202311:13 amRNSTotal Voting Rights
26th Apr 20234:32 pmRNSResult of AGM
26th Apr 20237:00 amRNSQ1 Trading Statement
3rd Apr 20234:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20233:05 pmRNSTotal Voting Rights
27th Mar 20233:44 pmRNSDirector/PDMR Shareholding
22nd Mar 20233:00 pmRNSAnnual Report 2022 and Notice of AGM 2023
13th Mar 20231:57 pmRNSDirectorate Change
13th Mar 202312:19 pmRNSUK Government Self Remediation Contract Signed
7th Mar 20235:33 pmRNSHolding(s) in Company
7th Mar 20237:04 amRNSDirector Declaration
6th Mar 20235:02 pmRNSHolding(s) in Company
1st Mar 20237:00 amRNSFull Year Results
12th Jan 20237:00 amRNSTrading Statement
1st Dec 20225:30 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20225:25 pmRNSVoting Rights and Capital
8th Nov 20227:00 amRNSTrading Statement
1st Nov 20221:00 pmRNSTotal Voting Rights
1st Nov 20229:24 amRNSHolding(s) in Company
10th Oct 20222:24 pmRNSDirector/PDMR Shareholding
5th Oct 202210:26 amRNSHolding(s) in Company
4th Oct 20223:07 pmRNSDirector/PDMR Shareholding
3rd Oct 20222:12 pmRNSTotal Voting Rights
22nd Sep 20223:54 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.